Hengehold Capital Management LLC Increases Stake in STERIS plc (NYSE:STE)

Hengehold Capital Management LLC boosted its position in shares of STERIS plc (NYSE:STE) by 57.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,700 shares of the medical equipment provider’s stock after acquiring an additional 622 shares during the quarter. Hengehold Capital Management LLC’s holdings in STERIS were worth $349,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. West Coast Financial LLC boosted its holdings in shares of STERIS by 2.8% in the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after purchasing an additional 45 shares during the period. SkyView Investment Advisors LLC increased its stake in shares of STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after buying an additional 51 shares during the period. Central Pacific Bank Trust Division lifted its stake in STERIS by 65.5% in the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 76 shares during the period. Metis Global Partners LLC increased its position in STERIS by 1.6% during the 3rd quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider’s stock valued at $1,322,000 after purchasing an additional 84 shares during the period. Finally, Cranbrook Wealth Management LLC increased its holdings in STERIS by 4.3% during the fourth quarter. Cranbrook Wealth Management LLC now owns 2,159 shares of the medical equipment provider’s stock valued at $444,000 after buying an additional 90 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. JMP Securities reiterated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday, November 8th. Stephens reissued an “overweight” rating and issued a $260.00 price target on shares of STERIS in a report on Thursday, November 7th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Finally, StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $262.50.

STERIS Trading Down 0.6 %

STE stock opened at $217.25 on Friday. STERIS plc has a 12-month low of $197.82 and a 12-month high of $248.24. The business’s 50-day moving average is $211.60 and its 200 day moving average is $224.70. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The stock has a market cap of $21.44 billion, a price-to-earnings ratio of 49.60 and a beta of 0.84.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The company had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the company posted $2.03 EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. On average, sell-side analysts anticipate that STERIS plc will post 9.11 EPS for the current fiscal year.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th were paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.05%. The ex-dividend date was Tuesday, November 19th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insider Transactions at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the transaction, the senior vice president now directly owns 11,372 shares in the company, valued at $2,471,363.04. This represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.14% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.